Five drugs target CACNA1A for seven indications, including anxiety, insomnia and cardiovascular disease, and targeting LRRK2 is a trial drug DNL201 (ClinicalTrials.gov identifier: NCT0371070, https://clinicaltrials.gov/study/NCT03710707) that shows promising therapeutic potential against PD51. The gene discussed is LRRK2; the disease is cardiovascular disorder.